Related Experiment Videos
Suppression of melanoma cell motility factor receptor expression by retinoic acid
1Department of Tumor Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Abstract:
beta-All-trans-retinoic acid (RA) has been shown to inhibit the growth, enhance the differentiation, and suppress the transformed and metastatic properties of certain human and murine melanoma cells. This study examined the effect of RA on the level of a cell surface receptor (M(r) 78,000) (gp78) for an autocrine motility factor, which has been implicated in invasion and metastasis. Treatment of murine melanoma cell lines S91-C2, B16-F1, and K1735-P with RA (10 microM) for 5 days decreased the level of gp78 by 37, 72, and 92%, respectively, as revealed by immunoblotting with monoclonal antibodies raised against gp78. In contrast, RA had only a limited effect on gp78 levels in melanoma cell clones or variant cell lines that are resistant to the growth-inhibitory effects of RA (S91-C154, B16-F10, and K1735-Cl19). Further studies with K1735-P, the most sensitive cell line with respect to modulation of gp78, showed that the decrease in gp78 level required at least 1 microM RA and 4 to 5 days of treatment. The binding of anti-gp78 antibodies to the surface of intact RA-treated cells and to intracellular gp78 in permeabilized cells was also lower than in untreated cells. Furthermore, RA treatment decreased the induction of cell motility, on colloidal gold-coated glass coverslips, by anti-gp78 antibodies, which mimic the effect of autocrine motility factor. The RA-induced decrease in antibody-enhanced cell motility was similar to the time- and RA concentration-dependent decrease in the amount of gp78, suggesting that the two events are related. These results raise the possibility that the previously reported suppression by RA of tumor cell invasion and metastasis may be related, at least in part, to suppression of cell motility resulting from the decreased level of the autocrine motility factor receptor.
Insights
beta-All-trans-retinoic acid (RA) reduces melanoma cell motility by decreasing the autocrine motility factor receptor (gp78). This suggests RA may suppress metastasis by inhibiting cell movement, offering potential therapeutic insights.
Area of Science:
- Oncology
- Cell Biology
- Molecular Medicine
Background:
- beta-All-trans-retinoic acid (RA) is known to inhibit melanoma growth and metastasis.
- Autocrine motility factor (AMF) and its receptor (gp78) are implicated in cancer cell invasion and metastasis.
Purpose of the Study:
- To investigate the effect of RA on the expression of the AMF receptor (gp78) in melanoma cells.
- To determine if RA-induced changes in gp78 levels correlate with alterations in cell motility.
Main Methods:
- Murine melanoma cell lines were treated with RA (10 microM) for 5 days.
- gp78 levels were assessed using immunoblotting with specific monoclonal antibodies.
- Cell motility was measured using colloidal gold-coated glass coverslips.
- Antibody-mediated cell motility induction was used to mimic AMF effects.
Main Results:
- RA treatment significantly decreased gp78 levels in sensitive melanoma cell lines (S91-C2, B16-F1, K1735-P) by 37-92%.
- RA had minimal effect on gp78 levels in RA-resistant melanoma cell lines.
- RA treatment reduced antibody-induced melanoma cell motility, correlating with decreased gp78 levels.
Conclusions:
- RA suppresses melanoma cell motility, likely through downregulation of the gp78 receptor.
- This RA-induced reduction in gp78 may contribute to the previously observed suppression of tumor cell invasion and metastasis.